TW202122573A - 治療血管疾病之組成物及方法 - Google Patents

治療血管疾病之組成物及方法 Download PDF

Info

Publication number
TW202122573A
TW202122573A TW109129322A TW109129322A TW202122573A TW 202122573 A TW202122573 A TW 202122573A TW 109129322 A TW109129322 A TW 109129322A TW 109129322 A TW109129322 A TW 109129322A TW 202122573 A TW202122573 A TW 202122573A
Authority
TW
Taiwan
Prior art keywords
meso
vpc
cells
mir
hsa
Prior art date
Application number
TW109129322A
Other languages
English (en)
Chinese (zh)
Inventor
瑪麗亞 米洛祖
奴丹 普拉森
阿姆里塔 辛格
羅伯特 蘭札
Original Assignee
安斯泰來再生醫藥協會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 安斯泰來再生醫藥協會 filed Critical 安斯泰來再生醫藥協會
Publication of TW202122573A publication Critical patent/TW202122573A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
TW109129322A 2019-08-28 2020-08-27 治療血管疾病之組成物及方法 TW202122573A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962892724P 2019-08-28 2019-08-28
US62/892,724 2019-08-28

Publications (1)

Publication Number Publication Date
TW202122573A true TW202122573A (zh) 2021-06-16

Family

ID=72428364

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109129322A TW202122573A (zh) 2019-08-28 2020-08-27 治療血管疾病之組成物及方法

Country Status (13)

Country Link
US (1) US20220288131A1 (cg-RX-API-DMAC7.html)
EP (1) EP4022038A1 (cg-RX-API-DMAC7.html)
JP (2) JP7894203B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220049618A (cg-RX-API-DMAC7.html)
CN (1) CN115003794A (cg-RX-API-DMAC7.html)
AU (1) AU2020337444A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022003659A2 (cg-RX-API-DMAC7.html)
CA (1) CA3151636A1 (cg-RX-API-DMAC7.html)
IL (1) IL290891A (cg-RX-API-DMAC7.html)
MX (1) MX2022002418A (cg-RX-API-DMAC7.html)
PH (1) PH12022550392A1 (cg-RX-API-DMAC7.html)
TW (1) TW202122573A (cg-RX-API-DMAC7.html)
WO (1) WO2021041591A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114231481A (zh) * 2021-12-21 2022-03-25 中国人民解放军总医院 一种重编程真皮成纤维细胞为内皮祖细胞的化学诱导方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102411018B1 (ko) 2015-08-18 2022-06-20 아스텔라스 인스티튜트 포 리제너러티브 메디슨 임상 제제
EP4372079A4 (en) * 2021-07-15 2025-07-30 Astellas Pharma Inc PERICYTE-LIKE CELLS EXPRESSING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AT A HIGH LEVEL
JP2025523987A (ja) * 2022-07-19 2025-07-25 ルング・バイオテクノロジー・パブリック・ベネフィット・コーポレイション 内皮細胞を分化させる方法
CN118177150B (zh) * 2024-04-15 2024-12-03 中国医学科学院医学实验动物研究所 遗传多样性高血压小鼠模型的建立与基因转录调控分析

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007238660C1 (en) 2006-04-14 2013-11-07 Astellas Institute For Regenerative Medicine Hemangio-colony forming cells
BRPI0912201A2 (pt) 2008-05-06 2019-09-24 Advanced Cell Tech Inc células formadoras de colônias de hemangios e células de hemangio não enxertantes
WO2010001375A1 (en) * 2008-06-30 2010-01-07 University College Cork, National University Of Ireland, Cork Primitive vascular progenitor cells and uses thereof
US20110305672A1 (en) * 2008-07-25 2011-12-15 University Of Georgia Research Foundation, Inc. COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME
US20140045265A1 (en) * 2011-02-16 2014-02-13 Salk Institute For Biological Studies Robust and efficient differentiation of human pluripotent stem cells to multipotent vascular progenitors
WO2012168167A1 (en) * 2011-06-09 2012-12-13 F. Hoffmann-La Roche Ag Method for differentiation of pluripotent stem cells into vascular bed cells
JP6048839B2 (ja) * 2011-11-08 2016-12-21 国立大学法人名古屋大学 ｉＰＳ細胞由来血管前駆細胞シート及びその作製方法
PL2785359T3 (pl) 2011-11-30 2018-12-31 Astellas Institute For Regenerative Medicine Mezenchymalne komórki zrębowe i związane z nimi zastosowania
CA2896053A1 (en) 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Methods for production of platelets from pluripotent stem cells and compositions thereof
WO2015153586A1 (en) * 2014-03-31 2015-10-08 The Johns Hopkins University Pluripotent stem cell therapies for ischemic retinopathies
GB201408712D0 (en) * 2014-05-16 2014-07-02 Univ Leuven Kath Mesodermal progenitor cells
JP6691921B2 (ja) 2015-02-20 2020-05-13 ウィスコンシン アラムニ リサーチ ファンデーション 動脈内皮細胞集団の生成
WO2016185457A1 (en) * 2015-05-19 2016-11-24 Yeda Research And Development Co. Ltd. Methods of promoting lymphangiogenesis
JP6646311B2 (ja) * 2015-07-17 2020-02-14 国立大学法人京都大学 多能性幹細胞から中胚葉前駆細胞および血液血管前駆細胞への分化誘導法
CN108138129B (zh) 2015-07-17 2021-11-16 国立大学法人京都大学 血管内皮细胞的诱导方法
KR102411018B1 (ko) 2015-08-18 2022-06-20 아스텔라스 인스티튜트 포 리제너러티브 메디슨 임상 제제
EP3497204B1 (en) * 2016-08-10 2025-04-30 Indiana University Research & Technology Corporation Method for generating mesoderm and/or endothelial colony forming cell-like cells having in vivo blood vessel forming capacity
WO2019152483A1 (en) * 2018-01-30 2019-08-08 University Of Georgia Research Foundation, Inc. Methods for vascular construction and products therefrom

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114231481A (zh) * 2021-12-21 2022-03-25 中国人民解放军总医院 一种重编程真皮成纤维细胞为内皮祖细胞的化学诱导方法

Also Published As

Publication number Publication date
CN115003794A (zh) 2022-09-02
IL290891A (en) 2022-04-01
JP7894203B2 (ja) 2026-07-23
US20220288131A1 (en) 2022-09-15
WO2021041591A1 (en) 2021-03-04
MX2022002418A (es) 2022-03-22
PH12022550392A1 (en) 2022-12-19
BR112022003659A2 (pt) 2022-05-24
JP2026001090A (ja) 2026-01-06
AU2020337444A1 (en) 2022-03-24
KR20220049618A (ko) 2022-04-21
CA3151636A1 (en) 2021-03-04
EP4022038A1 (en) 2022-07-06
JP2022545737A (ja) 2022-10-28

Similar Documents

Publication Publication Date Title
JP7583524B2 (ja) 被包化肝組織
US20220288131A1 (en) Compositions and methods of treating vascular diseases
JP6010460B2 (ja) フィブリンおよびアガロース生体材料を用いる組織工学による、人工組織の製造
US9938503B2 (en) Differentiation of human iPS cells to human alveolar type II via definitive endoderm
HK1216235A1 (zh) 使用产後衍生细胞治疗外周血管疾病
JP2018531027A6 (ja) 多能性幹細胞からのヒト皮膚オルガノイドの誘導
JP2018531027A (ja) 多能性幹細胞からのヒト皮膚オルガノイドの誘導
JP2011525370A (ja) ヒト多能性幹細胞からヒト代用皮膚を調製するための方法
KR20080097226A (ko) 결막 조직 시스템
AU2011299327A1 (en) Tissue-specific differentiation matrices and uses thereof
JP2024520423A (ja) 弱接着細胞を収容するための二次マトリックスを有する生分解性組織スキャフォールド
Song et al. Plasma fibrin membranes loaded with bone marrow mesenchymal stem cells and corneal epithelial cells promote corneal injury healing via attenuating inflammation and fibrosis after corneal burns
EP4428227A1 (en) Production method for sheet-like retinal tissue
CN108066750A (zh) 干细胞及其分泌物用于治疗皮肤烧烫伤的新用途
CN108066824A (zh) 一种制备表皮缺损治疗药物的新方法
RU2843942C2 (ru) Композиции и способы лечения сосудистых заболеваний
Yang et al. Dead but functional liquid nitrogen‐treated umbilical cord mesenchymal stem cells accelerate full‐thickness skin wound healing
JP2024520424A (ja) 黄斑、中心および末梢網膜色素上皮細胞を生成する方法
US20110076254A1 (en) Porous scaffolds for stem cell renewal
CN108057131A (zh) 一种含有干细胞的新型试剂盒
Booth The Development of Vascularised 3D Tissue Engineering Constructs
HK40114369A (en) Production method for sheet-like retinal tissue
HK40110173A (en) Biodegradable tissue replacement implant and its use
CN114657122A (zh) 一种复合干细胞球的纳米多肽水凝胶及其制备方法和应用
Abu Bakar et al. Proliferation and differentiation of human hair follicle stem cells on chitosan-skin engineered template in vitro